🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/06/2019 122,00 125,80 121,60 123,20 +1,40% 3,44% 182.227
21/06/2019 121,40 121,90 119,60 121,50 -0,74% 1,89% 201.448
20/06/2019 122,00 123,90 120,80 122,40 +1,75% 2,54% 159.079
19/06/2019 118,00 122,40 117,50 120,30 +3,71% 4,15% 191.374
18/06/2019 112,00 116,80 111,30 116,00 +4,50% 4,91% 135.984
17/06/2019 110,20 113,00 108,20 111,00 +1,09% 4,36% 115.961
14/06/2019 112,00 112,60 107,60 109,80 +0,73% 4,46% 90.998
13/06/2019 111,40 115,40 108,40 109,00 +1,87% 6,28% 115.060
12/06/2019 106,40 108,50 104,80 107,00 +0,56% 3,48% 57.615
11/06/2019 105,90 108,40 105,70 106,40 +1,33% 2,55% 70.921
10/06/2019 107,40 107,60 105,00 105,00 -1,87% 2,42% 55.227
07/06/2019 108,60 109,60 107,00 107,00 +0,00% 2,39% 58.977
06/06/2019 108,00 109,90 106,30 107,00 -0,37% 3,33% 90.525
05/06/2019 111,50 112,00 106,50 107,40 -2,63% 4,93% 103.108
04/06/2019 111,60 111,60 108,30 110,30 -0,45% 2,96% 80.107
03/06/2019 110,50 111,30 108,20 110,80 +0,00% 2,81% 90.164
31/05/2019 113,00 113,00 109,70 110,80 -2,38% 2,92% 89.190
30/05/2019 116,00 116,00 112,80 113,50 -1,99% 2,76% 52.752
29/05/2019 118,00 118,80 113,70 115,80 -2,93% 4,32% 74.462
28/05/2019 120,00 122,00 118,30 119,30 -1,24% 3,08% 140.171
27/05/2019 122,30 122,80 119,90 120,80 -0,41% 2,37% 55.246
24/05/2019 117,80 121,70 117,40 121,30 +4,66% 3,65% 137.716
23/05/2019 115,70 116,70 113,20 115,90 -0,60% 3,03% 109.244
22/05/2019 119,20 122,40 116,30 116,60 -1,19% 5,12% 143.831
21/05/2019 113,40 118,50 113,40 118,00 +3,42% 4,50% 93.533
20/05/2019 114,70 115,60 112,10 114,10 -1,38% 3,05% 63.637
17/05/2019 115,40 116,30 113,80 115,70 +0,17% 2,17% 84.173
16/05/2019 111,70 115,90 111,30 115,50 +4,43% 4,12% 107.573
15/05/2019 107,90 110,90 106,80 110,60 +3,27% 3,80% 87.922
14/05/2019 102,30 107,60 102,20 107,10 +5,21% 5,28% 113.918